Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major
暂无分享,去创建一个
Filippo Cademartiri | V. Positano | A. Meloni | L. Cuccia | P. Ricchi | R. Righi | M. Gamberini | C. Gerardi | R. Lisi | V. Cecinati | L. Pistoia | G. Restaino
[1] H. Ardehali,et al. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease , 2022, Nature Reviews Cardiology.
[2] Xiangyu Zhang,et al. Iron in Cardiovascular Disease: Challenges and Potentials , 2021, Frontiers in Cardiovascular Medicine.
[3] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[4] R. de Caterina,et al. Myocardial iron overload by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach that correlates with cardiac complications , 2021, Journal of Cardiovascular Magnetic Resonance.
[5] V. Positano,et al. National networking in rare diseases and reduction of cardiac burden in thalassemia major , 2021 .
[6] OUP accepted manuscript , 2021, European Heart Journal.
[7] V. Positano,et al. Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Well‐Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric CMR Approach , 2020, Journal of magnetic resonance imaging : JMRI.
[8] M. Dweck,et al. Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.
[9] V. Positano,et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine , 2018, British journal of haematology.
[10] V. Positano,et al. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach , 2018, European heart journal cardiovascular Imaging.
[11] Aref Albakri. Iron overload cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnostic and clinical management using iron chelators , 2018 .
[12] A. Maggio,et al. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major , 2017, British journal of haematology.
[13] D. Pennell,et al. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging , 2017, Hematology.
[14] V. Positano,et al. Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients , 2015, Journal of cardiovascular medicine.
[15] V. Positano,et al. Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study , 2015, Circulation. Cardiovascular imaging.
[16] V. Positano,et al. Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy. , 2015, European heart journal cardiovascular Imaging.
[17] V. Positano,et al. Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. , 2014, International journal of cardiology.
[18] Milton Packer,et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.
[19] M. Lombardi,et al. Myocardial iron overload in thalassaemia major. How early to check? , 2014, British journal of haematology.
[20] V. Positano,et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study , 2013, British journal of haematology.
[21] D. Pennell,et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. , 2013, Circulation.
[22] H. Rienhoff,et al. The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages , 2013, British journal of haematology.
[23] V. Positano,et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy , 2013, Journal of Cardiovascular Magnetic Resonance.
[24] D. Pennell,et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major , 2012, Haematologica.
[25] M. R. Lamprecht,et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.
[26] V. Positano,et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study , 2011, Haematologica.
[27] Massimo Lombardi,et al. Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload , 2011, Journal of magnetic resonance imaging : JMRI.
[28] C. Jellis,et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension , 2010, Heart.
[29] Dudley J Pennell,et al. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[30] D. Weatherall. Thalassemia as a global health problem: recent progress toward its control in the developing countries , 2010, Annals of the New York Academy of Sciences.
[31] V. Positano,et al. Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients , 2010, Magnetic resonance in medicine.
[32] Raffaella Origa,et al. BETA THALASSEMIA , 2018, The Professional Medical Journal.
[33] V. Positano,et al. Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopathies , 2009, Haematologica.
[34] Luigi Landini,et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia , 2009, Int. J. Medical Informatics.
[35] Massimo Midiri,et al. Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron , 2009, Journal of magnetic resonance imaging : JMRI.
[36] P. Moraitis,et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study , 2009, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[37] V. Positano,et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major , 2009, Heart.
[38] V. Positano,et al. Influence of myocardial fibrosis and blood oxygenation on heart T2* values in thalassemia patients , 2009, Journal of magnetic resonance imaging : JMRI.
[39] J. Wood. Cardiac Complications in Thalassemia Major , 2009, Hemoglobin.
[40] T. Coates,et al. Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.
[41] Matthew W. Darlison,et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[42] S. Ha,et al. Effect of deferasirox (ICL670) on arterial function in patients with beta‐thalassaemia major , 2008, British journal of haematology.
[43] Massimo Midiri,et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts , 2007, NMR in biomedicine.
[44] E. Gotsis,et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. , 2007, Haematologica.
[45] V. Positano,et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.
[46] V. Positano,et al. Evaluation of the efficacy of oral deferiprone in β‐thalassemia major by multislice multiecho T2* , 2006, European journal of haematology.
[47] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[48] J. Porter. Practical management of iron overload , 2001, British journal of haematology.
[49] C. McLaren,et al. Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.
[50] J. Clegg,et al. Thalassemia — a global public health problem , 1996, Nature Medicine.
[51] P. Toutouzas,et al. Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .
[52] R. Adolph,et al. Cardiovascular effects of anemia. , 1972, American heart journal.